Schott Pharma stock trades at EUR 24.93 as revenue grows
Published on 09/29/2026 at 13:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Schott Pharma stock (ISIN DE000A3ENQ51) was trading at EUR 24.93 at Lang & Schwarz on September 29, 2026, at 1:42 p.m. CEST. The latest quarterly figures combine 9.87 percent revenue growth with a lower earnings-per-share figure, while JPMorgan's new coverage supplies a concrete valuation reference.
Revenue reaches EUR 281.76 million
According to finanzen.ch on September 29, 2026, Schott Pharma reported EUR 281.76 million in revenue for the quarter ended June 30, 2026, compared with EUR 256.46 million in the prior-year quarter. That equals growth of 9.87 percent and shows that demand for pharmaceutical containment and delivery systems continued to expand.
The earnings mix was less favorable. EPS came in at EUR 0.26 in the quarter, down from EUR 0.30 a year earlier, so revenue growth did not translate into higher quarterly per-share earnings.
JPMorgan sets EUR 27.10 target
On September 15, 2026, Finanznachrichten reported that JPMorgan initiated coverage with an Overweight rating and a EUR 27.10 price target. Analyst Philip Omnou sees average annual earnings growth of 14 percent through 2029, citing structural trends and Schott Pharma's position in injectable-drug packaging.
The target stands 8.70 percent above the Lang & Schwarz price of EUR 24.93. For investors, the central question is whether the revenue advance can eventually improve EPS as well.
Q4 results are due December 10
The next scheduled checkpoint is the Q4 2026 results release on December 10, 2026, according to finanzen.ch. That report should clarify whether the June-quarter revenue pace was accompanied by improving profitability.
Stock trades at EUR 24.93
Schott Pharma stock was trading at EUR 24.93 at Lang & Schwarz on September 29, 2026, at 1:42 p.m. CEST. The quote is below the EUR 27.10 JPMorgan target, while the stock's 52-week range was EUR 12.62 to EUR 30.25 as of September 29, 2026.
Schott Pharma stock facts
- Company: SCHOTT Pharma AG & Co. KGaA
- ISIN: DE000A3ENQ51
- WKN: A3ENQ5
- Ticker: 1SXP
- Primary exchange: Xetra
- Price Lang & Schwarz as of September 29, 2026, 1:42 p.m. CEST: EUR 24.93
- Market capitalization: EUR 3.8 billion (as of September 29, 2026)
- 52-week range: EUR 12.62-EUR 30.25 (as of September 29, 2026)
- Sector / Industry: Healthcare / Medical Instruments and Supplies
- Index membership: SDAX
- Next earnings date: December 10, 2026
